CorMedix Inc.
NASDAQ Global MarketTotal Valuation
CorMedix Inc. carries a market capitalization of 684.10M, placing it among publicly traded companies globally. Its enterprise value stands at 479.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 684.10M |
| Enterprise Value | 479.80M |
Share Statistics
CorMedix Inc. currently has 78.40M shares outstanding.
| Shares Outstanding | 78.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
CorMedix Inc. trades at a trailing price-to-earnings ratio of 2.83. The price-to-sales ratio is 1.28, and the price-to-book ratio stands at -3.72.
| PE Ratio | 2.83 |
| PS Ratio | 1.28 |
| PB Ratio | -3.72 |
| P/TBV Ratio | 13.40 |
| P/FCF Ratio | 2.92 |
| P/OCF Ratio | 2.59 |
Enterprise Valuation
On an enterprise value basis, CorMedix Inc. trades at an EV/EBITDA multiple of 2.19 and an EV/FCF ratio of 2.36. The EV/Sales ratio of 1.20 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2.48 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.20 |
| EV / EBITDA | 2.19 |
| EV / EBIT | 2.48 |
| EV / FCF | 2.36 |
Financial Position
CorMedix Inc. maintains a current ratio of 2.98, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.15, indicating elevated leverage, while an interest coverage ratio of 78.86 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.98 |
| Quick Ratio | 2.59 |
| Debt / Equity | 33.15 |
| Debt / EBITDA | 0.66 |
| Interest Coverage | 78.86 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 37.51 |
| Return on Invested Capital (ROIC) | 53.07 |
| Return on Capital Employed (ROCE) | -117.98 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.97 |
Taxes
Over the trailing twelve months, CorMedix Inc. has paid 4.01M in income taxes, reflecting an effective tax rate of 2.16.
| Income Tax | 4.01M |
| Effective Tax Rate | 2.16 |
Stock Price Statistics
CorMedix Inc.'s stock has declined approximately -23.64273% over the past 52 weeks. The 50-day moving average sits at 8.11, while the 200-day moving average is 8.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.64273% |
| 50-Day Moving Average | 8.11 |
| 200-Day Moving Average | 8.95 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CorMedix Inc. generated 400.05M in revenue and converted that into 181.01M in net income, yielding earnings per share of 2.10. EBITDA reached 218.60M, while operating income came in at 193.67M.
| Revenue | 400.05M |
| Gross Profit | 343.39M |
| Operating Income | 193.67M |
| Pretax Income | 185.02M |
| Net Income | 181.01M |
| EBITDA | 218.60M |
| EBIT | 193.67M |
| Earnings Per Share (EPS) | 2.10 |
Balance Sheet
CorMedix Inc. holds 178.09M in cash and equivalents against 144.89M in total debt, resulting in a net debt position of -33.20M. Total book value stands at -137.90M, with working capital of 254.34M providing operational flexibility.
| Cash & Cash Equivalents | 178.09M |
| Total Debt | 144.89M |
| Net Debt | -33.20M |
| Equity (Book Value) | -137.90M |
| Book Value Per Share | -1.83 |
| Working Capital | 254.34M |
Cash Flow
CorMedix Inc. produced 197.69M in operating cash flow over the past twelve months. After subtracting -2.98M in capital expenditures, free cash flow totaled 194.71M - equivalent to 2.58 per share.
| Operating Cash Flow | 197.69M |
| Capital Expenditures | -2.98M |
| Free Cash Flow | 194.71M |
| FCF Per Share | 2.58 |
Margins
CorMedix Inc. operates with a gross margin of 85.83, reflecting its pricing power and cost economics. The operating margin of 48.41 and net profit margin of 45.25 provide insight into operational efficiency.
| Gross Margin | 85.83 |
| Operating Margin | 48.41 |
| Pretax Margin | 46.25 |
| Profit Margin | 45.25 |
| EBITDA Margin | 54.64 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -42.94 |
| FCF Yield | 34.26 |
Stock Splits
CorMedix Inc.'s most recent stock split took place on March 26, 2019 with a 5:1 split ratio.
| Last Split Date | 3/26/2019 |
| Split Ratio | 5:1 |
Scores
CorMedix Inc. posts an Altman Z-Score of 3.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.57 |